Three new studies
Study results being presented at the 21st annual meeting of the American Society for Bone and Mineral Research this week could lead to significant improvement in the treatment of osteoporosis in post menopausal women. The studies involved Fosamax, a drug produced by Merck Frosst Canada & Co.
“It is our clinical experience that some post menopausal women still have osteoporosis, despite receiving hormone replacement therapy,” said Dr. Jacques Brown, Head of the Rheumatology Division, Centre hospitalier universitaire de Québec, Laval University. “While Fosamax is not approved in Canada for the treatment of osteoporosis in post menopausal women receiving HRT, these results – the first involving such a large female population – are encouraging.”
According to Dr,. Brown, the study results “seem to demonstrate” that Fosamax not only provides additional increases in bone mineral density (BMD) in women already on hormone replacement therapy, but prevents rapid bone loss and increases BMD, even if hormone replacement therapy is discontinued.